China GLP-1RA market is thriving with Eli Lilly’s recent NMPA approval, surpassing Novo in the oral medication sector.
Recent Posts
- China GLP-1RA market sees Best Proven Approval from Eli Lilly
- Trade Margins on Anti-Cancer Drugs: Clear Price Cuts Ahead
- What Should Consumers Know Before Purchasing Peptides in the UK?
- Methylprednisolone Injection approval: Safe and Proven USFDA Success
- Sun Pharma shares fall: Q2 profit plunges 36%



